High density lipoproteins in health and in disease

Journal of Investigative Medicine

Volumn 47, Issue 1, 1999, Pages 31-42

  Genest Jr , Jacques ^a   Marcil, Michel ^b   Denis, Maxime ^b   Yu, Lu ^b  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN;

ACTIVE TRANSPORT; CORONARY ARTERY DISEASE; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MUTATION; REVIEW;

APOLIPOPROTEIN A-I; BIOLOGICAL TRANSPORT, ACTIVE; CHOLESTEROL; CORONARY DISEASE; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MUTATION;

EID: 0032619021     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (129)

1. The Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). J Am Med Inform Assoc 1993;269:3015-23.
2. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
3. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA 1986;256:2835-8.
4. Havel RJ, Kane JP. Structure and metabolism of plasma lipoproteins. In: CR Scriver, AL Beaudet, WS Sly and D Valle, eds. The metabolic and molecular basis of inherited disease, 7th edition. McGraw-Hill, USA. 1995;1841-51.
5. Eisenberg S. High density lipoprotein metabolism. J Lipid Res 1984;25:1017-58.
6. Tuajuanda C, Jordan-Starck J-S, White DP, Aronow BJ, Harmony JAK. Apolipoprotein J: a membrane policeman? Curr Opin Lipidol 1992;3:75-85.
7. Kounnas MZ, Loukinova EB, Stefansson S, Harmony JA, Brewer BH, Strickland KD, Argraves WS. Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin. J Biol Chem 1995;270:13070-5.
8. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995;96:3005-8.
9. Takahashi Y, Chiba H, Matsuno K, Akita H, Hui SP, Nagasaka H, Nakamura H, Kobayashi K, Tandon NN, Jamieson GA. Native lipoproteins inhibit platelet activation induced by oxidized lipoproteins. Biochem Biophys Res Comm 1996;222:453-9.
10. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996:271:518-21.
11. Smith AB, Hajduck SL. Identification of haptoglobin as a natural inhibitor of trypanocidal activity in human serum. Proc Natl Acad Sci USA 1995;92:10262-6.
12. Smith AB, Esko JD, Hajduk SL. Killing of trypanosomes by the human haptoglobin-related protein. Science 1995;268:284-6.
13. Cockerill GW, Rye K-A, Gamble JR, Vadas MA, Barter PJ. HDL inhibit cytokine-induced expression of endothelial cell adhesion moleculae. Arterioscler Thromb Vasc Biol 1995;15:1987-94.
14. Vinals M, Martinez-Gonzalez J, Badimon JJ, Badimon L. HDL-induced prostacyclin release in smooth muscle cells in dependent on cyclooxygenase-2 (Cox-2). Arterioscler Thromb Vasc Biol 1997;17:3481-8.
15. Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PWG. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994;35:871-82.
16. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawbwr TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14.
17. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham Study. Arch Intern Med 1981;141:1128-31.
18. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153:2209-16
19. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124:S11-20.
20. Stokes J III, Kannel WB, Wolf PA, Copples A, D'Agostino RB. The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years follow-up in the Framingham Study. Circulation 1987;75:65-73.
21. Kannel WB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol 1983;52:98-128.
22. Goldbourt U, Medalie JH. High-density lipoprotein cholesterol and incidence of coronary heart disease - the Israeli Ischemic Heart Disease Study. Am J Epidemiol 1979;109:296-308.
23. Genest J Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR Anderson KM, Wilson PWF, Salem DN, Schaefer EJ. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992;19:792-802.
24. Barter PJ, Rye K-A. High density lipoproteins and coronary heart disease. Atherosclerosis 1995;121:1-12.
25. Gaziano JM, Henneckens CH, O'Donnell CJ, Breslow JL. Fasting triglycerides, high density lipoprotein, and risk of myocardial infarction. Circulation 1997;96:2520-5.
26. Weber M, McNicoll S, Lussier-Cacan S, Marcil M, Connelly P, Rondeau C, Latour Y, Connelly P, Davignon J, Genest J Jr. Plasma lipoproteins, apolipoprotein B, apolipoprotein E phenotypes and metabolic factors in premature CAD in French Canadians. Can J Cardiol 1997;13:253-60.
27. Assmann G. The role of triglycerides in coronary artery disease: lessons from the Prsopective Cardiovascular Study in Munster. Am J Cardiol 1992;79:10H-13H.
28. Laakso M, Lehto S, Penttilä I, Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993;88:1421-30.
29. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. New Eng J Med 1991;325:373-81.
30. Cholesterol Lowering in the Patient with Coronary artery Disease. National Institutes of Health, National Heart, Lung and Blood Institute; National Cholesterol Education Program Adult Treatment Panel 2. (NIH Publ. 97-3794).
31. The Lipid Research Clinics Population Studies Data Book. Vol. 1 The prevalence study. Washington, D.C.: Department of Health and Human Services, Public Health Service, (NIH Publ. 80-1527).
32. Austin MA. Genetic epidemiology of LDL subclass phenotypes. Ann Med 1992;24:472-81.
33. Frohlich J, Fodor G, McPherson R, Genest J, Langer N. For the Health Canada Working Party on the diagnosis and treatment of hypercholesterolemia and other dyslipidemias. Rationale for and outline of new Canadian guidelines. (Submitted)
34. Genest J Jr, McNamara JR, Salem DN, Cohn SD, Millar JS, Wilson PFW, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991;67:1185-9.
35. Genest J Jr, Bard JM, Fruchart JC, Ordovas JM, Schaefer EJ. Familial Hypoalphalipoproteinemia in Premature Coronary Artery Disease. Arterioscler Thromb Vasc Biol 1993;13:1728-37.
36. Karathanasis SK. Lipoprotein metabolism: high density lipoproteins In: Lusis AJ, Rotter RS, Sparkes RS, eds. Molecular genetics of coronary artery disease. Candidate genes and processes in atherosclerosis Monographs Hum Genet Basel: Kruger, 1992;14:140-71.
37. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211-28.
38. Li Z, McNamara JR, Ordovas JM, Schaefer EJ. Analysis if high density lipoproteins by a modified gradient gel electropheresis method. J Lipid Res 1994;35:1698-1711.
39. Shumaker VN, Puppione DL. Sequential flotation ultracentrifugation. Methods Enzymol 1986;128:155-70.
40. Puchois P, Kandoussi A, Feivet P, Fourier JL, Bertrand M, Koren E, Fruchart JC. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1991;68:35-41.
41. Genest J Jr, Bard JM, Fruchart JC, Ordovas JM, Wilson PWF, Schaefer EJ. Plasma apolipoproteins A-I, A-II, B, E, and CIII containing particles in men with premature coronary artery disease. Atherosclerosis 1991;90:149-57.
42. Kawano M, Miida T, Fielding CJ, Fielding PE. Quantitation of Pre-b-HDL dependent and nonspecific components of the total efflux of cellular cholesterol and phospholipid. Biochem 1993;32:5025-8.
43. Brinton EA, Eisenberg S, Breslow JL. Increased apoA-I and apoA-II fractional catabolic rate in patients with low high density lipoprotein cholesterol levels with or without hypertriglyceridemia. J Clin Invest 1991;87:536-44.
44. Emmerich J, Verges B, Tauveron I, Rader D, Sammaritano-Fojo S, Schaefer J, Ayrault-Jarrier M, Thieblot P, Brewer B Jr. Familial HDL deficiency due to marked hypercatabolism of normal apo AI. Arterioscler Thromb Vasc Biol 1993;13:1299-1306.
45. Horowitz BS, Goldberg IJ, Merab J, Vanni TM, Ramakrishnan R. Increased plasma and renal clearance of an exchangeable pool of apolipoproteins A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 1993;91:1743-52.
46. Le AN, Ginsberg HN. Heterogeneity of apolipoprotein A-I turnover with reduced concentrations of plasma high density lipoprotein cholesterol. Metabolism 1988;37:614-7.
47. Rader DJ, Gregg RE, Meng MS, Schaefer JR, Zech LA, Benson MD, Brewer HB Jr. In vivo metabolism of a mutant apolipoprotein apo AIIowa, associated with hypoalphalipoproteinemia and systemic amyloidosis. J Lipid Res 1992;33:755-63.
48. Rader DJ, Ikewaki K, Duverger N, Feuerstein I, Zech L, Connor W, Brewer HB Jr. Very low high-density lipoproteins without coronary atherosclerosis. Lancet 1993;342:8885.
49. Schaefer EJ, Ordovas JM. Metabolism of apolipoproteins A-I, A-II, and A-IV. Methods Enzymol 1986;129:420-43.
50. Breslow JL. Lipoprotein transport abnormalities underlying heart disease susceptibility. Annu Rev Med 1991;42:357-71.
51. Roma P, Gregg RE, Meng MS, Ronan R, Zech LA, Franceschini G, Sirtori CR, Brewer HB. In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with hypoalphalipoproteinemia. J Clin Invest 1993;91:1445-52.
52. Johnson JJ, Chacko GK, Phillips MC, Rothblat GH. The efflux of lysosomal cholesterol from cells. J Biol Chem 1990;265:5546-53.
53. De la Llera Moya M, Atger V, Paul JL, Fournier N, Moatti N, Giral P, Friday KE, Rothblat G. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb Vasc Biol 1994;14:1056-65.
54. Davidson WS, Gillotte KL, Lund-Kats S, Johnson WJ, Rothblat GH Phillips MC. The effect of high density lipoprotein phospholipid acyl chain composition on the efflux of cellular cholesterol. J Biol Chem 1995;270:5882.
55. McKnight GL, Reasoner J, Gilbert T, Sundquist KO, Hokland B, McKernan PA, Champagne J, Johnson CJ, Bailey MC, Holly R. Cloning and expression of a cellular HDL binding protein that is up-regulated by cholesterol loading of cells. J Biol Chem 1992;267:12131-41.
56. Oram JF, Mendez AJ, Slotte JP, Johnson TF. High density lipoprotein apolipoproteins mediate removal of sterol from intracellular pools but not from plasma membranes of cholesterol-loaded fibroblasts. Arterioscler Thromb Vasc Biol 1991;11:403-14.
57. Kruse C, Grunweller A, Notbom H, Kugler S, Purschke WG, Muller PK. Evidence for a novel cytoplasmic tRNA-protein complex containing the KH-multidomain protein vigilin. Biochem J 1996;320:247-52.
58. Plenz G, Kugler S, Schnittger S, Rieder H, Fonatsch C, Muller PK. The human vigilin gene: identification, chromosomal localization and expression patterns. Hum Genet 1994;93:575-82.
59. Mendez AJ, Oram JF, Bierman EL. Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. J Biol Chem 1991;266:10104-11.
60. Deeg MA, Garver WS, Bierman EL, Oram JF. HDL stimulates phosphorylation of 18 and 80 kDa proteins in cholesterol-loaded human skin fibroblasts. Circulation 1993;88:Abs 1215.
61. Drobnick W, Mollers C, Resink T, Schmitz G. Activation of phosphatidyl-specific phospholipase C in response to HDL3 and LDL is markedly reduced in cultured fibroblasts from Tangier patients. Aterioscler Thromb Vasc Biol 1995;15:1369-77.
62. Walter M, Reinecke H, Gerdes U, Nofer J-R, Hobbel G, Seedorf U, Assman G. Defective regulation of phosphatidyl-choline-specific phospholipases C and D in a kindred with Tangier disease. J Clin Invest 1996;98:2315-23.
63. Deeg MA, Bowen RF, Oram JF, Bierman EL. High density lipoproteins stimulate mitogen-activated protein kinases in human skin fibroblasts. Atheroscler Thromb Vasc Biol 1997;17:1667-74.
64. Lange Y. Disposition of intracellular cholesterol in human fibroblasts. J Lipid Res 1991;32:329-39.
65. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
66. Lange Y, Matthies HJG. Transfer of cholesterol from its site of synthesis to the plasma membrane. J Biol Chem 1984;259:14624-30.
67. Lange Y, Steck JL. Cholesterol-rich intracellular membranes: a precursor to the plasma membrane. J Biol Chem 1985;260:15592-6.
68. Lange Y, Swaisgood MH, Ramos B, Steck TL. Plasma membranes contain half the phospholipid and 90% of the cholesterol and sphingomyelin in cultured human fibroblasts. J Biol Chem 1989;264:3786-93.
69. Liscum L, Underwood KW. Intracellular cholesterol transport and compartmentation. J Biol Chem 1995;270:15443-6.
70. Coxey RA, Pentchev PG, Campell G, Blanchette-Mackie EJ. Differential accumulation of cholesterol in Golgi compartments of normal and Niemann-Pick type C fibroblasts incubated with LDL: a cytochemical freeze-fracture study. J Lipid Res 1993;34:1165-76.
71. Mendez AJ. Monensin and Brefeldin A inhibit high density lipoprotein-mediated cholesterol efflux from cholesterol-enriched cells. J Biol Chem 1995;270:5891-900.
72. Johnson WJ, Fisher RT, Philllips MC, Rothblat GH. Efflux of newly synthesized cholesterol and biosynthetic sterol intermediates from cells. J Biol Chem 1995;270:25037-46.
73. Fielding, PE, Fielding CJ. Plasma membrane caveolae mediate the efflux of cellular free cholesterol. Biochemistry 1995;34:14288-92.
74. Smart EJ, Ying YS, Donzell WC, Anderson RG. A role for caveolin in transport of cholesterol from endoplasmic reticulum to plasma membrane. J Biol Chem 1996;271:29427-35.
75. Lisanti MP, Tang Z, Scherer PE, Kubler E, Koleske AJ, Sargiacomo M. Caveolae, transmembrane signaling, and cellular transformation. Mol Membr Biol 1995;12:121-4.
76. Walter M, Gerdes U, Seedorf U, Assmann G. The apolipoprotein AI-induced mobilization of cellular cholesterol is impaired in fibroblasts from Tangier disease subjects. Biochem Biopyhs Res Commun 1994;205:850-6.
77. Rogler G, Trumbach B, Klima B, Lackner KJ, Schmitz G. HDL-mediated efflux of intracellular cholesterol is impared in fibroblasts from Tangier disease patients. Arterioscler Thromb Vasc Biol 1995;15:683-690.
78. Francis GA, Knopp RH, Oram JF. Defective removal of cellular cholesterol and phospholipids by apolipoprotein AI in Tangier disease. J Clin Invest 1995;96:78-87.
79. Hajjar DP, Haberland ME. Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. J Biol Chem 1997;272:22975-8.
80. 2. Clin Biochem 1997;30:221-5.
81. Banka CL. High density lipoprotein and lipoprotein oxidation. Curr Opin Lipidol 1996;7:139-42.
82. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882-91.
83. Raeven E, Tsai L, Azhar S. Cholesterol uptake by the selective pathway of ovarian granulosa cells: early intracellular events. J Lipid Res 1995;36:1602-17.
84. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopoly-saccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994;180:1025-35.
85. Hager KM, Hajduk SL. Mechanism of resistance of African trypanosomes to cytotoxic human HDL. Nature 1997;385:823-6.
86. Raper J, Nussenzweig V, Tomlinson S. The main lytic factor of Trypanosoma brucei brucei in normal human serum is not high density lipoprotein. J Exp Med 1996;183:1023-9.
87. Yuan Y, Jackson SP, Newnham HH, Mitchell CA, Salem HH. An essential role for lysophosphatidylcholine in the inhibition of platelet aggregation by secretory phospholipase A2. Blood 1995;86:4166-74.
88. Fujimoto Y, Tsunomori M, Muta E, Yamamoto T, Nishida H, Sakuma S, Fujita T. High density lipoprotein inhibits platelet 12-lipoxygenase activity. Res Comm Mol Pathol Pharmacol 1994;85:355-8.
89. Genest J Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner JL, Meyers RH, Silberman SR, Wilson PWF, Salem DN, Schaefer EJ. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-33.
90. Williams RR, Hunt SC, Hopkins PN, Stults BM, Wu LL, Hasstedt SJ, Barlow GK, Stephenson SH, Lalouel J-M, Kuida H. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA 1988;259:3579-86.
91. Hopkins PN, Hunt SC, Wu LL, Williams GH, Williams RR. Hypertension, dyslipidemia and insulin resistance: links in a chain or spokes on a wheel. Curr Opin Lipidol 1996;7:241-53.
92. Mahaney MC, Blangero J, Rainwater DL, Comuzzie AG, Van de Berg JL, Stern MP, MacCluer JW, Hixson JE. A major locus influencing plasma high-density lipoprotein cholesterol levels in the San Antonio Family Heart Study. Segregation and linkage analyses. Arterioscler Thromb Vasc Biol 1995;15:1730-9.
93. Hegele RA, Brunt JH, Connelly PW. Multiple genetic determinants of variation of plasma lipoproteins in Alberta Hutterites. Arterioscler Thromb Vasc Biol 1995;15:861-71.
94. Williams RR, Hunt SC, Hopkins PN, Wu LL, Hasstedt SJ, Berry TD, Barlow GK, Stults BM, Schumacher MC, Ludwig EH et al. Genetic basis of familial dyslipidemia and hypertenson: 15-year results from Utah. Am J Hypertens 1993;6:319S-27S.
95. Heiba IM, De Meester CA, Xia YR, Diep A, George VT, Amos CI, Srinivasan SR, Berenson GS, Elston RC, Lusis AJ. Genetic contributions to quantitative lipoprotein traits associated with coronary artery disease: analysis of a large pedigree from the Bogalusa Heart Study. Am J Med Genet 1993;47:875-83.
96. Breslow JL. Familial disorders of high density lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS and Valle D, eds. The metabolic and molecular basis of inherited disease, 7th edition. McGraw-Hill, USA. 1995:2031-52.
97. Ng NS, Leiter LA, Vezina C, Connelly PW, Hegele RA. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein AI deficiency in a family with analphalipoproteinemia. J Clin Invest 1994;93:223-9.
98. Ordovas JM, Cassidy DK, Civeira F, Bisgaier CL, Schaefer EJ. Familial apolipoprotein A-I, C-III and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem 1989;264:16339-42.
99. Takata K, Saku K, Ohta T, Takata M, Bai H, Jimi S, Liu R, Sato H, Kajiyama G, Arakawa. A new case of apo AI deficiency showing codon 8 nonsense mutation of the apo AI gene without evidence of coronary artery disease. Atheroscler Thromb Vasc Biol 1995;15:1866-74.
100. Moriyama K, Sasaki J, Takada Y, Matsanuga A, Fukui J, Albers JJ, Arakawa K. A cysteine containing truncated apo AI variant associated with HDL deficiency. Atheroscler Thromb Vasc Biol 1996;16:1416-23.
101. Funke H, von Eckardstein A, Pritchard PH, Karas M, Albers JJ, Assmann G. A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin:cholesterol-acyltransferase deficiency, and corneal opacities. J Clin Invest 1991;87:371-6.
102. Romling R, von Eckardstein A, Funke H, Motti C, Fragiacomo GC, Noseda G, Assmann G. A nonsense mutation in the apolipoprotein A-I gene is associated with high-density lipoprotein deficiency and peri-orbital xanthelasmas. Arterioscler Thromb Vasc Biol 1994;14:1915-22.
103. Deeb SS, Cheung MC, Peng R, Wolf AC, Stern R, Albrs JJ, Knopp RH. A mutation in the human apolipoprotein A-I gene. Dominant effect on the level and characteristics of plasma high density lipoproteins. J Biol Chem 1991;266:13654-60.
104. Miccoli R, Bertolotto A, Navalesi R, Odoguardi L, Boni A, Wessling J, Funke H, Wiebusch H, Eckardstein A, Assmann G. Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease. Circulation 1996;94:1622-8.
105. Funke H, von Eckardstein A, Pritchard PH, Hornby AE, Wiebusch H, Motti C, Hayden MR, Dachet C, Jacotot B, Gerdes U, Faegeman O, Albers JJ, Colleoni N, Catapano A, Frohlich J, Assmann G. Genetic and phenotypic heterogeneity in familial lecithin:cholesterol acyltransferase (LCAT) deficiency. J Clin Invest 1993;91:677-83.
106. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 1997;38:191-205.
107. Serfaty-Lacrosniere C, Civiera F, Lanzberg A, Isaia P, Berg J, Janus ED, Smith MP Jr, Pritchard PH, Frohlich J, Lees RS. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 1994;107:85-98.
108. Assmann G, von Eckardstein A, Brewer HB Jr. Familial high density lipoprotein deficiency: Tangier disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D. eds. The metabolic and molecular basis of inherited disease, 7th edition. McGraw-Hill, USA, 1995:2053-72.
109. Ma Y, Henderson HE, Murthy V, Roederer G, Monsalve MV, Clarke LA, Normand T, Julien P, Gagne C, Lambert M. A mutation in the human lipoprotein lipase gene as the most common cause of familial chylomicronemia in French Canadians. N Engl J Med 1991;324:1761-6.
110. 250→Asn) in exon 6 of the human lipoprotein lipase gene causes chylomicronemia in patients of different ancestries. Genomics 1992;13:649-53.
111. Hegele RA, Tu L, McGuire GF, Connelly PW. Molecular basis and allele specific screening of Apo CII St Michaels. Clin Biochem 1992;25:309-12.
112. Hirano K, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y, Ishigami M, Sakai N, Kameda-Takemura K, Matsazuwa Y. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Atheroscler Thromb Vasc Biol 1997;17:1053-9.
113. Calabresi L, Franceschini G. High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein. Curr Opin Lipidol 1997;8:219-24.
114. Vigushin DM, Gough J, Allan D, Algaunal A, Penne B, Pettigrew NM. Familial nephropathy amyloidosis. QJM 1994;87:149-54.
115. Soutar AK. Systemic amyloidosis Arg 26 apo AI. Proc Natl Acad Sci USA 1992;89:7389-93.
116. 1-HDL and influences efflux of cholesterol into plasma. J Lipid Res 1997;38:1242-53.
117. von Eckardstein A, Funke H, Henke A, Altland K, Benninghoven A, Assmann G. Apolipoprotein A-I variants. Naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I. J Clin Invest 1989;84:1722-30.
118. Carlson LA, Holmquist L. Evidence for deficiency of high density lipoprotein lecithin:cholesterol acyltransferase activity (LCAT) in Fish-Eye disease. Acta Medica Scandivanvia 1985;218:189-96.
119. Frohlich J, McLeod R, Pritchard PH, Fesmire J, McConathy W. Plasma lipoprotein abnormalities in heterozygous for lecithin:cholesterol-acyltransferase deficiency. Metabolism 1988;37:3-8.
120. Remaley AT, Schumacher JA, Farsi JA, Nazih BD, Brewer HB Jr. Decreased reverse cholesterol transport from Tangier disease fibroblasts. Acceptor specificity and effects of brefeldin on lipid efflux. Atheroscler Thromb Vasc Biol 1997;17:1813-21.
121. Marcil M, Boucher B, Frohlich J, Davignon J, Solymoss BC, Genest J Jr. Severe Familial HDL deficiency in French Canadian kindred: biochemical and molecular characterization. Arterioscler Thromb Vasc Biol 1995;15:1015-24.
122. Batal R, Tremblay M, Krimbou L, Mamer O, Davignon J, Genest J Jr. Cohn JS. Familial deficiency characterized by hypercatabolism of mature apo AI but not proapoAI. Atheroscler Thromb Vasc Biol 1998;18:655-66.
123. Marcil M, Lu Yu L, Boucher B, Oram J, Genest J Jr. Cellular cholesterol transport and efflux from fibroblasts is abnormal in subjects with familial HDL deficiency. Atheroscler Thromb Vasc Biol 1999;19:159-69.
124. Cheung MC, Mendez AJ, Wolf AC, Knopp RH. Characterization of apolipoprotein A-I and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling Tangier disease and their effects on intracellular cholesterol efflux. J Clin Invest 1993;19:522-9.
125. Carstea ED, Morris JA, Coleman KG, Loftus SK, Zhang D, Cummings C, Gu J, Rosenfeld MA, Pavan WJ, Krizman DB, Nagle J, Polymeropoulos MH, Sturley SL, Ioannu YA, Higgins ME, Comly M, Cooney A, Brown A, Kaneski CR, Blanchette-Mackie EJ, Dwyer NK, Neufeld EB, Chang TY, Liscum L, Table DA. Neimann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 1997;277:228-31.
126. Huang Y, von Eckardstein A, Wu S, Maeda N, Assman G. A plasma lipoprotein containing only apolipoprotein E and with γ mobility on electropheresis releases cholesterol from cells. Proc Natl Acad Sci USA 1994;91:1834-8.
127. 2-LpE and α-LpE. J Lipid Res 1997;38:35-48.
128. von Eckardstein A, Huang Y, Wu S, Funke H, Noseda G, Assmann G. Reverse cholesterol transport in plasma of patients with different forms of familial HDL deficiency. Arterioscler Thromb Vasc Biol 1995;15:691-703.
129. Schaefer EJ, Levy RI. Pathogenesis and management of lipoprotein disorders. N Eng J Med 1985;312:1300-10.